20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level
Go back to 20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level| (NASDAQ: AIDX) | Delayed: 0.47 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.47 | 52 Week High | $ | |||
| Open | $0.47 | 52 Week Low | $ | |||
| Day High | $0.47 | P/E | N/A | |||
| Day Low | $0.47 | EPS | $ | |||
| Volume | 20 | |||||
| (NASDAQ: AIDX) | Delayed: 0.47 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.47 | 52 Week High | $ | |||
| Open | $0.47 | 52 Week Low | $ | |||
| Day High | $0.47 | P/E | N/A | |||
| Day Low | $0.47 | EPS | $ | |||
| Volume | 20 | |||||

